Tablets, film coated: biconvex, oblong, light pink color, on one party – an engraving (depending on a dose) "012" or "018", on another – the stylized letter "e" (on 10 pieces in blisters, on 1 blister in a cardboard pack);
Tablets, film coated (for children): biconvex, round, light pink color, on one party – an engraving "03", on another – the stylized letter "e" (on 10 pieces in blisters, on 1 blister in a cardboard pack).

Structure of 1 tablet:

Active agent: a hydrochloride of a feksofenadin – 120 or 180 mg;
Auxiliary components (120/180 mg): croscarmellose sodium – 24/36 mg; prezhelatinizirovanny starch – 120/180 mg; microcrystallic cellulose – 133/199,5 mg; magnesium stearate – 3/4,5 mg;
Film cover: a gipromelloz (E15) – 2,84/4,26 mg; a gipromelloz (E5) – 1,89/2,835 mg; povidone – 0,51/0,765 mg; titanium dioxide (E171) – 2,025/3,038 mg; colloid silicon dioxide – 0,73/1,095 mg; a macrogoal 400 – 3,94/5,91 mg; dye iron oxide (pink mix – mix of red iron oxide (E172) and titanium dioxide (E171)) – 0,025/0,038 mg; dye iron oxide (yellow mix – mix of yellow iron oxide (Е 172) and titanium dioxide (Е 171)) – 0,04/0,06 mg.

Structure of 1 tablet for children:

Active agent: a hydrochloride of a feksofenadin – 30 mg;
Auxiliary components: prezhelatinizirovanny corn starch, croscarmellose sodium, magnesium stearate, microcrystallic cellulose;
Film cover: gidroksipropilmetiltsellyuloz (gipromelloz) of E-5, gidroksipropilmetiltsellyuloz (gipromelloz) of E-15, dye iron oxide [pink and yellow mix], anhydrous colloid silicon dioxide, povidone, macrogoal 400, titanium dioxide.

Indications to use

Allegra is appointed for reduction of symptoms of the following diseases:

Seasonal allergic rhinitis (on 120 mg);
Chronic idiopathic small tortoiseshell (on 180 mg).

Contraindications

Absolute:

Age up to 6 years (for tablets for children) and up to 12 years (for tablets);
Pregnancy and period of a lactation;
Hypersensitivity to drug components.

Relative (Allegr is appointed with care in the presence of the following diseases / states):

Chronic liver/renal failure (because of limited clinical experience of use of drug for this group of patients);
Advanced age (because of limited clinical experience of use of drug for this group of patients);
Cardiovascular diseases, including in the anamnesis (Allegra can cause tachycardia and heartbeat).

Route of administration and dosage

Allegra is accepted inside, it is desirable – before meal.

The recommended dosing mode for adults and children of 12 years (a daily dose with frequency rate of reception once a day):

Seasonal allergic rhinitis: 120 mg;
Chronic small tortoiseshell: 180 mg.

To children of 6-11 years appoint Allegra for children with the maintenance of 30 mg of active ingredient.

Side effects

Probable side effects:

Very often (≥1% and <10%): headache, drowsiness, dizziness, nausea;
Seldom (<1%): diarrhea, heartbeat, tachycardia, nervousness, sleeplessness, weakness, sleep disorders or unusual dreams, such as nightmares;
Very seldom (≥0,01% and <0,1%): a small tortoiseshell, a dieback, an itch and other reactions of hypersensitivity, including system anaphylactic reactions, a Quincke's edema, breath difficulty, a hyperemia of integuments, an asthma.

Special instructions

The interval between Allegra's reception and antacids with the maintenance of a hydroxide of magnesium or aluminum has to make at least 2 hours.

In need of performance of work, the demanding high concentration of attention and bystry psychomotor reactions, previously it is necessary to check individual reaction on фексофенадин.

Medicinal interaction

At the combined use of Allegra with ketokonazoly or erythromycin plasma concentration of a feksofenadin increases by 2-3 times, significant lengthening of an interval of QTc is not observed.

Frequency of development of side reactions does not depend on that, Allegra as monotherapy or in combination with other medicines is applied.

Reception of antacids with the content of magnesium or aluminum in 15 minutes prior to Allegra's reception can lead to reduction of bioavailability of a feksofenadin (most likely because of binding in digestive tract).